Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
20 hedge funds and large institutions have $2.55M invested in Seelos Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
54% more funds holding
Funds holding: 13 → 20 (+7)
30% less capital invested
Capital invested by funds: $3.66M → $2.55M (-$1.11M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
+$1.36M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$491K |
| 3 |
TAM
Tocqueville Asset Management
New York
|
+$186K |
| 4 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
+$145K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$81.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWP
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
|
-$41K |
| 2 |
Renaissance Technologies
New York
|
-$37.2K |
| 3 |
Squarepoint
New York
|
-$3.72K |
SEEL Hedge Fund Activity: Q1 2020 in Review
20 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2020, worth a combined $2.55M — down 30% from $3.66M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SEEL positions and 1 closed out — a net gain of 8 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Uniplan Investment Counsel, adding an estimated $1.36M. The largest seller was MYCIO Wealth Partners, exiting entirely with an estimated $41K sold.
- 20 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2020, up from 13 in Q4 2019.
- Funds reported $2.55M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2020, down 30% quarter-over-quarter.
- 9 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2020 and 1 closed out, a net change of +8 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2020 was Uniplan Investment Counsel, an estimated $1.36M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2020 was MYCIO Wealth Partners, an estimated $41K sold.
Based on aggregated 13F filings for Q1 2020.